Cure My Disease

Don't miss your cure!

 Log in / Sign up

Old drug, new hope? bumetanide trial targets Alzheimer's

NCT ID NCT06052163

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests bumetanide, a diuretic used for decades, in 40 people with early Alzheimer's. Researchers want to see if it is safe and might help slow cognitive decline. The study is double-blind and placebo-controlled, meaning neither patients nor doctors know who gets the real drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bumetanide (a diuretic, also known as Bumex)
What this could lead to
If successful, this could point toward a new, repurposed treatment to slow cognitive decline in early Alzheimer's disease.
What could go wrong
This is a small, early-phase trial focused on safety, not proof of effectiveness. Bumetanide can cause dehydration and electrolyte imbalances, especially in older adults.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Stanford University

    RECRUITING

    Stanford, California, 94305, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.